GLP-1 Receptor Agonists Tied to Increased Risk for Alopecia

TUESDAY, Aug. 4, 2026 (HealthDay News) -- Glucagon-like peptide-1 (GLP-1) receptor agonists are associated with an increased risk for alopecia in adults with type 2 diabetes, according to a study published online July 22 in The BMJ.Huilin Tang, Ph.D., from the University of Pennsylvania in Philadelphia, and colleagues examined the association between GLP-1 receptor agonists and the risk for incident alopecia in adults with type 2 diabetes. The analysis included 12,004 GLP-1 receptor agonist initiators versus 15,221 sodium-glucose cotransporter-2 (SGLT-2) inhibitor initiators, as well as 11,964 GLP-1 receptor agonist initiators versus 11,238 dipeptidyl peptidase-4 (DPP-4) inhibitor initiators.The researchers found that use of GLP-1 receptor agonists was associated with a higher risk for alopecia than use of SGLT-2 inhibitors (hazard ratio [HR], 1.37) or DPP-4 inhibitors (HR, 1.68). Associations persisted across sensitivity and subgroup analyses, with attenuation after negative control outcome calibration. The association was specific to nonscarring alopecia (SGLT-2 inhibitors: HR, 1.53; DPP-4 inhibitors: HR, 1.72)."Use of GLP-1 receptor agonists was associated with an increased risk of nonscarring alopecia in adults with type 2 diabetes," the authors write. "Although the absolute risk is low, awareness of this potential effect may help to inform treatment decisions."Abstract/Full Text.Sign up for our weekly HealthDay newsletter

GLP-1 Receptor Agonists Tied to Increased Risk for Alopecia

Related Stories

Review Shows Antihistamines Offer No Meaningful Benefit in Atopic Dermatitis

2017 to 2022 Saw More Than Doubling in Use of GLP-1 Receptor Agonists

Review Shows Most Obesity Drugs Do Not Aid Quality of Life, Heart Health

GLP-1 Receptor Agonist Use Does Not Increase Insulin Discontinuation With Type 2 Diabetes